For immediate release |
11 February 2010 |
("AMS" or the "Group")
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, will announce its preliminary results for the year ended 31 December 2009 on Tuesday 9 March 2010.
A briefing for analysts will be held at 9am on the day of the results at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.
For further information, please contact:
Advanced Medical Solutions Group plc |
|
Don Evans, Chief Executive Officer Mary Tavener, Finance Director Chris Meredith, Chief Operating Officer |
Tel: +44 (0) 1606 545508 |
|
|
Buchanan Communications |
|
Mark Court / Stasa Filiplic/Jennie Spivey |
Tel: +44 (0) 20 7466 5000 |
|
|
Investec Bank plc |
Tel: +44 (0) 20 7597 5970 |
Gary Clarence / Daniel Adams |
|
Notes to Editors:
Advanced Medical Solutions develops and manufactures products for the $15 billion global woundcare market.
Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.
The advanced woundcare products are based on the moist wound healing principle. AMS uses its in-house technology to provide a vertically integrated 'one stop shop' for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.
AMS' technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection.
AMS' products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors.